Submit a comment
Citation Information: J Clin Invest. 1973;52(2):454-462. https://doi.org/10.1172/JCI107202.
Abstract
Cellular accumulation of L-cystine in rat kidney cortex in vivo has been studied using L-[35S]cystine. The L-[35S]cystine radioactivity in plasma decreases to less than 10% of the initially calculated value by 15 min. Four 35S-containing intracellular products of L-cystine metabolism were identified including cystine, cysteine, reduced glutathione, and an as yet unidentified compound. The latter is probably taurine, cysteinesulphinate, or cysteic acid. Cellular accumulation of these products was found to be more rapid in vivo than in vitro. Cellular accumulation of the products of L-cystine metabolism was found to be essentially unchanged in the presence of ureter ligation. Unlabeled L-lysine administered simultaneously with L-[35S]cystine, in both the presence and absence or ureter ligation, enhanced the cellular accumulation of intracellular metabolic products of L-[35S]cystine. Simultaneous 35S cellular accumulation and L-cystine clearance studies were performed both in the presence and absence of L-lysine. L-Lysine enhanced cellular accumulation of 35S-products despite an accompanying increase in L-cystine clearance. The results are interpreted as evidence for a dissociation between cellular accumulation and transepithelial transport. This evidence for independent luminal transport and peritubular cellular accumulation could explain the apparent paradox in the disease cystinuria where there appears to be a luminal transport defect for L-cystine, but no defect for cellular accumulation of L-cystine metabolic products in vitro.
Authors
Warren E. Greth, Samuel O. Their, Stanton Segal
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)